Viatris
Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.
DitchCarbon Score
How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viatris's score of 29 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Viatris's reported carbon emissions
In 2023, Viatris reported total carbon emissions of approximately 4,105,000 kg CO2e, with Scope 2 emissions accounting for about 295,000 kg CO2e and Scope 3 emissions remaining significant at 4,105,000 kg CO2e. In 2022, the company achieved a total of approximately 395,630 kg CO2e, all from Scope 2 emissions, indicating a focus on reducing indirect emissions associated with energy consumption. Viatris has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030 from a 2020 baseline. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions, which encompass purchased goods and services, capital goods, and upstream transportation and distribution, within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the company's long-term goal of achieving net zero emissions by 2050 for its UK operations. Overall, Viatris is actively working towards significant emissions reductions while addressing its broader environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 299,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 653,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viatris is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
